Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET

Company Representatives

Tom McCourt - Chief Executive Officer

Mike Shetzline - Chief Medical Officer

Sravan Emany - Chief Financial Officer

Matt Roache - Director of Investor Relations

Conference Call Participants

David Amsellem - Piper Sandler

Operator

Good morning. My name is Stephanie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Second Quarter 2022 Investor Update Conference Call. [Operator Instructions]. Thank you.

Matt Roache, Director of Investor Relations, you may begin your conference.

Matt Roache

Thank you, Stephanie. Good morning and thanks for joining us for our second quarter 2022 investor update. Our Press Release issued this morning can be found on our website. Today’s call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially.

A discussion of these statements and risk factors is available on the current Safe Harbor statement slide as well as under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2021, and in our future SEC filings.

All forward-looking statements speak as of the date of this presentation, and we undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement to, and not any substitute for or superior to GAAP measures. To the extent applicable, please refer to the tables at the end of our Press Release for reconciliations of these measures to the most directly comparable GAAP measures.

During today’s call, Tom McCourt, our CEO, will review our strategic priorities and provide an update on the commercial performance of LINZESS. Mike Shetzline, our Chief Medical Officer, will discuss our pipeline and Sravan Emany our, our Chief Financial Officer will review our financial results and guidance.

Today’s webcast include slides. So, for those of you dialing in, please go to the Events section of our website to access the accompanying slides separately.

With that, I’ll turn the call over to Tom.

Tom McCourt

Thanks, Matt. Good morning, everyone. And thanks for joining us today as we share our second quarter results. The positive momentum across our business continued in the second quarter, as demonstrated by robust LINZESS prescription demand growth, advancement of our clinical programs, completion of our share repurchase program, and repayment of our 2022 convertible notes.